# Biote

Type: Company (BTMD)

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/biote
Canonical HTML page: https://gethealthbrief.com/entity/biote

## Timeline

- **2027**: NXT 41X Launch — Anticipated commercial launch of Elutia's next-gen drug-eluting biomaterial.
- **2026-Q2**: Bumble 2.0 Launch — Targeted launch of AI-enabled platform experience.
- **2026-03-11**: Codexis CDMO Expansion — Announced three major CDMO agreements with Bachem, Nitto Avecia, and Axolabs.
- **2026**: Elutia FDA Milestone — Expected FDA submission for NXT 41X product line.
- **2025-12-31**: Elutia Divestiture — Completed $88M sale of bioenvelope business to Boston Scientific.

## Recent coverage (1 stories)

### MedTech and Life Sciences Pivot Toward AI Efficiency and Asset Optimization
2026-03-12 00:13:28 · Sentiment: Positive · Impact: 6/10 · Sources: 9

The Q4 2025 earnings cycle for mid-cap healthcare and life sciences firms reveals a strategic shift toward high-margin AI integration and portfolio streamlining. Companies like Elutia and Codexis are leveraging divestitures and technology transfers to shore up balance sheets, while AI-driven productivity gains are becoming a primary differentiator in clinical and operational workflows.
Full story: https://gethealthbrief.com/story/medtech-life-sciences-ai-efficiency-asset-optimization

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.